Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
Morgan Stanley Maintains Overweight on HOOKIPA Pharma, Lowers Price Target to $18
Morgan Stanley analyst Vikram Purohit maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Overweight and lowers the price target from $19 to $18.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
HOOKIPA Pharma Q2 EPS $(0.52) Beats $(0.53) Estimate, Sales $5.38M Beat $5.13M Estimate
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.53) by 1.89 percent. This is a 85.71 percent decrease over losses of $(0.28) per share from the
Recap: HOOKIPA Pharma Q2 Earnings
Shares of HOOKIPA Pharma (NASDAQ:HOOK) moved higher by 3.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 85.71% over the past year to ($0.52), which beat the estimate of ($0.53).